FDA Issues Emergency Use Authorizations for COVID-19 Treatment and Prevention

Summary

The Food and Drug Administration (FDA) has issued five Emergency Use Authorizations (EUAs) for drug and biological products to combat the COVID-19 pandemic. These authorizations were granted in response to requests from Baxter Healthcare Corporation, the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, Eli Lilly and Company, and Regeneron Pharmaceuticals, Inc.